Skip to main content

Table 2 Univariate analysis of survival for patients with ANPC

From: Leucopenia and treatment efficacy in advanced nasopharyngeal carcinoma

 

All population

Cycles <4 population

Cycles > =4 population

Variable

OS

DMFS

OS

DMFS

OS

DMFS

Leucopenia

      

Mild VS Absent

     

HR(95 %CI)

0.70(0.57-0.86)

0.79(0.63-0.98)

0.73(0.57-0.92)

0.87(0.66-1.14)

0.56(0.38-0.86)

0.56(0.37-0.86)

p

0.001

0.038

0.009

0.309

0.007

0.008

Severe VS Absent

     

HR(95 %CI)

0.77(0.60-0.97)

1.01(0.78-1.31)

0.86(0.63-1.16)

1.10(0.79-1.54)

0.59(0.38-0.90)

0.73(0.46-1.14)

P

0.030

0.927

0.320

0.554

0.016

0.166

Mild VS Severe

     

HR(95%CI)

0.91(0.76-1.09)

0.77(0.64-0.93)

0.85(0.66-1.08)

0.78(0.61-1.02)

0.98(0.75-1.28)

0.77(0.58-1.09)

p

0.314

0.007

0.191

0.069

0.887

0.058

Gender

      

HR(95 %CI)

0.62(0.51-0.75)

0.69(0.57-0.84)

0.63(0.50-0.79)

0.71(0.55-0.91)

0.61(0.45-0.84)

0.67(0.49-0.2)

P

<0.001

<0.001

<0.001

0.007

0.002

0.015

Age

      

HR(95 %CI)

1.84(1.59-2.14)

1.09(0.93-1.27)

1.93(1.59-2.34)

1.14(0.94-1.39)

1.73(1.36-2.19)

1.01(0.77-1.30)

P

<0.001

0.304

<0.001

0.191

<0.001

0.941

T-classification

     

HR(95 %CI)

1.27(1.14-1.40)

1.09(0.99-1.22)

1.27(1.11-1.45)

1.11(0.96-1.27)

1.26(1.07-1.49)

1.08(0.91-1.27)

P

<0.001

0.092

0.001

0.157

0.007

0.375

N-classification

     

HR(95CI)

1.56(1.43-1.70)

1.65(1.50-1.81)

1.70(1.51-1.90)

1.75(1.54-1.97)

1.39(1.21-1.60)

1.52(1.32-1.76)

P

<0.001

<0.001

<0.001

<0.001

<0.001

<0.001

Radiotherapy

      

HR(95 %CI)

0.80(0.68-0.94)

0.91(0.76-1.08)

0.88(0.70-1.10)

1.03(0.82-1.30)

0.69(0.54-0.89)

0.75(0.58-0.97)

P

0.008

0.273

0.264

0.764

0.005

0.030

  1. Abbreviations: OS: overall survival; DMFS: distant metastasis-free survival; HR: hazard ratio; CI: confidence interval; ANPC: advanced nasopharyngeal carcinoma